BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 24149177)

  • 41. Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis.
    Kubo T; Shimose S; Fujimori J; Furuta T; Ochi M
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):46-53. PubMed ID: 26008753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma.
    Dehner CA; Armstrong AE; Yohe M; Shern JF; Hirbe AC
    Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680895
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma.
    Bonvini P; Zin A; Alaggio R; Pawel B; Bisogno G; Rosolen A
    Br J Cancer; 2013 Dec; 109(12):3084-91. PubMed ID: 24149177
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma.
    Gasparini P; Casanova M; Villa R; Collini P; Alaggio R; Zin A; Bonvini P; Antonescu CR; Boldrini R; Caserini R; Moro M; Centonze G; Meazza C; Massimino M; Bergamaschi L; Luksch R; Chiaravalli S; Bisogno G; Zaffaroni N; Daidone MG; Sozzi G; Ferrari A
    Oncotarget; 2016 Sep; 7(37):58903-58914. PubMed ID: 27385213
    [TBL] [Abstract][Full Text] [Related]  

  • 45. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
    Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
    Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
    Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
    J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
    Lee JS; Lim SM; Rha SY; Roh JK; Cho YJ; Shin KH; Yang WI; Kim SH; Kim HS
    J Clin Pathol; 2014 Jan; 67(1):33-9. PubMed ID: 23922356
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression and clinical relevance of MET and ALK in Ewing sarcomas.
    Fleuren ED; Roeffen MH; Leenders WP; Flucke UE; Vlenterie M; Schreuder HW; Boerman OC; van der Graaf WT; Versleijen-Jonkers YM
    Int J Cancer; 2013 Jul; 133(2):427-36. PubMed ID: 23335077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anaplastic lymphoma kinase status in rhabdomyosarcomas.
    Yoshida A; Shibata T; Wakai S; Ushiku T; Tsuta K; Fukayama M; Makimoto A; Furuta K; Tsuda H
    Mod Pathol; 2013 Jun; 26(6):772-81. PubMed ID: 23307059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.
    van Gaal JC; Flucke UE; Roeffen MH; de Bont ES; Sleijfer S; Mavinkurve-Groothuis AM; Suurmeijer AJ; van der Graaf WT; Versleijen-Jonkers YM
    J Clin Oncol; 2012 Jan; 30(3):308-15. PubMed ID: 22184391
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
    Schulte JH; Bachmann HS; Brockmeyer B; Depreter K; Oberthür A; Ackermann S; Kahlert Y; Pajtler K; Theissen J; Westermann F; Vandesompele J; Speleman F; Berthold F; Eggert A; Brors B; Hero B; Schramm A; Fischer M
    Clin Cancer Res; 2011 Aug; 17(15):5082-92. PubMed ID: 21632861
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anaplastic lymphoma kinase in human cancer.
    Barreca A; Lasorsa E; Riera L; Machiorlatti R; Piva R; Ponzoni M; Kwee I; Bertoni F; Piccaluga PP; Pileri SA; Inghirami G;
    J Mol Endocrinol; 2011 Aug; 47(1):R11-23. PubMed ID: 21502284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.
    Cao L; Yu Y; Bilke S; Walker RL; Mayeenuddin LH; Azorsa DO; Yang F; Pineda M; Helman LJ; Meltzer PS
    Cancer Res; 2010 Aug; 70(16):6497-508. PubMed ID: 20663909
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
    Kelleher FC; McDermott R
    Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.